| Biomarker ID | 504 |
| PMID | 20035634 |
| Year | 2009 |
| Biomarker | ANXA5; APLP2; COL1A2; CRIM1; ECHS1; HMGB1; MAP3K5; NGFRAP1; NPM1; NUB1; PDIA3; PLA2G2A; ROCK1; TEGT; TMEM16G; TMEM69; TRAF4; VCAN; VCP; VDAC1; |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Differentially Expressed: ANXA5 [4.28 fold]; APLP2 [2.83 fold]; COL1A2 [2.02 fold]; CRIM1 [3.23 fold]; ECHS1 [1.89 fold]; HMGB1 [4.68 fold]; MAP3K5 [2.98 fold]; NGFRAP1 [3.95 fold]; NPM1 [3.07 fold]; NUB1 [1.62 fold]; PDIA3 [2.40 fold]; PLA2G2A [3.00 fold]; ROCK1 [9.76 fold]; TEGT [2.77 fold]; TMEM16G [0.35 fold]; TMEM69 [2.77 fold]; TRAF4 [2.59 fold]; VCAN [2.92 fold]; VCP [2.75 fold]; VDAC1 [5.41 fold]; |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | 11 of 20 significantly verified genes are involved in apoptotic processes (PDIA3, MAP3K5, ANXA5, VDAC1, NGFRAP1, TEGT, NPM1, VCP, TRAF4, HMGB1, and ROCK1) |
| Experiment | Gleason Score 6 Vs Gleason Score (8-10) |
| Type of Biomarker | Prognostic |
| Cohort | 65 RNA samples derived from 13 benign and 52 prostate cancer tissue comprising 25 samples with Gleason Score (GS) 6 and 27 samples with GS 8-10 |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.05 |
| Method Used | qRT-PCR |
| Clinical | No |
| Remarks | Another 2500 differentially expressed genes between prostate cancer and benign samples are available from supplementry material of the paper |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |